EQS-News: Viromed Medical AG: Anna Heinen appointed to the Supervisory Board
|
EQS-News: Viromed Medical AG
/ Key word(s): Personnel
Viromed Medical AG: Anna Heinen appointed to the Supervisory Board Rellingen, March 19, 2026 – Viromed Medical AG (“Viromed”; ISIN: DE000A40ZVN7), a medical technology company and pioneer in cold plasma technology, has appointed a new member to its Supervisory Board. Anna Heinen was appointed to the Supervisory Board by court order. She succeeds Frank Otto, who resigned from the Supervisory Board for personal reasons. Dr. Thomas Gutschlag, Chairman of the Supervisory Board of Viromed Medical AG, states: “I am very pleased that we have gained a qualified Supervisory Board member in Anna Heinen with proven expertise in the areas of corporate strategy, transformation, and governance. With her experience, she will provide important impetus for the further development of our company. At the same time, on behalf of the entire Supervisory Board and the Management Board, I would like to express our sincere thanks to Frank Otto for his commitment over the past three years. He provided valuable support to Viromed during the company’s crucial growth phase.” Anna Heinen has been a member of the Supervisory Board of Smartaxxess Operation AG, a fintech company focused on planning, valuation and financing for small and medium-sized enterprises, since 2022. She is also a qualified Supervisory Board member according to Deutsche Börse standards, as well as being a member of ARMID – Aufsichtsräte Mittelstand in Deutschland e.V. Professionally, Ms. Heinen has been responsible for the corporate strategy of e-fellows.net GmbH & Co. KG, an HR service provider owned by McKinsey & Company and Zeitverlag, for many years. Since 2023, she has also supported medium-sized companies regularly in succession and transformation processes as an independent management consultant.
About Viromed Medical AG Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential. www.viromed-medical-ag.de
Contact Viromed E-Mail: kontakt@viromed-medical.de
Press contact E-Mail: viromed@kirchhoff.de
19.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Viromed Medical AG |
| Hauptstraße 105 | |
| 25462 Rellingen | |
| Germany | |
| E-mail: | kontakt@viromed-medical.de |
| Internet: | https://www.viromed-medical-ag.de/ |
| ISIN: | DE000A40ZVN7 |
| WKN: | A40ZVN |
| Listed: | Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX |
| EQS News ID: | 2294118 |
| End of News | EQS News Service |
|
|
2294118 19.03.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | ||
| Sales1 | 0,00 | 0,00 | 0,00 | 0,00 | 1,37 | 9,00 | 80,00 | |
| EBITDA1,2 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | 0,00 | 0,00 | |
| EBITDA-Margin3 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
| EBIT1,4 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | 0,50 | 8,00 | |
| EBIT-Margin5 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 5,56 | 10,00 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | 0,00 | 0,00 | |
| Net-Margin6 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
| Cashflow1,7 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | 0,00 | 0,00 | |
| Earnings per share8 | 0,00 | 1,23 | -0,01 | -0,01 | -0,02 | 0,04 | 0,07 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Bernd Lenzen
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Viromed Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A40ZVN | DE000A40ZVN7 | AG | 117,45 Mio € | 04.05.2022 | 9F5FMR3F+R3 | |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 44,62 | 0,00 | 0,00 | 290,00 | 5,88 | -1.067,73 | 85,73 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 06.07.2026 | 30.09.2024 | 30.06.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +1,56% | +33,06% | +52,63% | +124,81% | +20,83% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
